ISMRC 2023 Final Programme

19 SESSION 7 Latest developments in Liquid biopsy- based monitoring of MRD Chairs: Ellen Heitzer, Austria Claus Lindbjerg Andersen, Denmark 09:00 – 09:20 a.m. Screening of patient samples with ad- vanced non-small cell lung cancer in circulating cell-free DNA using three targeted assays Lea Payen, France 09:20 – 09:40 a.m. Standardizing and harmonizing MRD assessment using ctDNA to enable cli- nical implementation to improve patient outcomes Mohan Bolisetty, USA 09:40 – 10:00 a.m. Comprehensive liquid biopsy analysis as a tool for early detection of minimal residual disease in breast cancer Athina Markou, Greece 10:00 – 10:30 a.m. Coffee Break SESSION 8 Immunotherapy for prevention of metastatic progression – Part II Chairs: Simon Joosse, Germany Gunhild von Amsberg, Germany 10:30 – 11:00 a.m. Immunotherapy of lung cancer – current status in metastatic and non-metastatic NSCLC Martin Reck, Germany 11:00 – 11:30 a.m. Liquid biopsy & lung cancer immuno- therapy: Between hope and hype in routine practice Paul Hofman, France 11:30 a.m. – 12:00 p.m. Omics-driven identification of thera- peutic resistance in metastatic mela- noma patients receiving immune check- point inhibition Christoffer Gebhardt, Germany 12:00 – 12:30 p.m. Outlook of clinical applications of Liquid Biopsy Howard Scher, USA 12:30 – 01:00 p.m. Young Investigator Awards Chairs: Klaus Pantel, Germany Catherine Alix-Panabières, France 01:00 – 01:15 p.m. Concluding Remarks Klaus Pantel, Germany Catherine Alix-Panabières, France Thursday, 4 May 2023 – Scientific Programme